QT
VRDN icon

Quantbot Technologies’s Viridian Therapeutics VRDN Stock Holding History

Quantbot Technologies’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-530
Closed -$16.5K – 2194
2025
Q4 		$16.5K Buy
+530
New +$14.5K ﹤0.01% 1576
2025
Q2 		– Sell
-21,131
Closed -$285K – 1975
2025
Q1 		$285K Buy
21,131
+12,556
+146% +$214K 0.01% 1048
2024
Q4 		$164K Buy
+8,575
New +$186K 0.01% 1096
2023
Q2 		– Sell
-700
Closed -$17.8K – 1992
2023
Q1 		$17.8K Buy
+700
New +$22.4K ﹤0.01% 1362

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Quantbot Technologies's VRDN Position: Q1 2026 in Review

Quantbot Technologies sold out of Viridian Therapeutics (VRDN) in Q1 2026, closing a stake of 530 shares — an estimated $16.5K sold.

Quantbot Technologies first reported a position in VRDN in Q1 2023 and held it in 4 quarters. The position peaked at $285K in Q1 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Quantbot Technologies reported no remaining Viridian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Quantbot Technologies sold 530 Viridian Therapeutics shares in Q1 2026, an estimated $16.5K.
  • Quantbot Technologies first reported a position in Viridian Therapeutics in Q1 2023 and held it in 4 quarters.
  • Quantbot Technologies's Viridian Therapeutics position peaked at $285K in Q1 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Quantbot Technologies's 13F filing for Q1 2026, filed 13 May 2026.